• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对《氟维司群在常规临床实践中治疗内分泌抵抗性绝经后晚期乳腺癌女性患者的疗效》一文的更正

Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.

作者信息

Blancas I, Fontanillas M, Conde V, Lao J, Martínez E, Sotelo M J, Jaen A, Bayo J L, Carabantes F, Illarramendi J J, Gordon M M, Cruz J, García-Palomo A, Mendiola C, Pérez-Ruiz E, Bofill J S, Baena-Cañada J M, Jáñez N M, Esquerdo G, Ruiz-Borrego M

机构信息

Hospital Universitario Clínico San Cecilio, Complejo Hospitalario Universitario, C/Dr. Oloriz, 16, 18012, Granada, Spain.

Hospital Clinic de Barcelona, illarroel, 170, 08036, Barcelona, Spain.

出版信息

Clin Transl Oncol. 2018 Dec;20(12):1631-1632. doi: 10.1007/s12094-018-1956-7.

DOI:10.1007/s12094-018-1956-7
PMID:
30284231
Abstract

A sentence under 'Results' heading in the Abstract section was published incorrectly. The correct sentence should read as follows.

摘要

摘要部分“结果”标题下的一个句子发表有误。正确的句子应如下所示。

相似文献

1
Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.对《氟维司群在常规临床实践中治疗内分泌抵抗性绝经后晚期乳腺癌女性患者的疗效》一文的更正
Clin Transl Oncol. 2018 Dec;20(12):1631-1632. doi: 10.1007/s12094-018-1956-7.
2
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.氟维司群治疗常规临床实践中内分泌耐药的绝经后晚期乳腺癌女性的疗效。
Clin Transl Oncol. 2018 Jul;20(7):862-869. doi: 10.1007/s12094-017-1797-9. Epub 2017 Nov 24.
3
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.帕博西尼联合氟维司群治疗绝经前激素受体阳性晚期乳腺癌患者的效果:PALOMA-3 研究结果
Oncologist. 2017 Sep;22(9):1028-1038. doi: 10.1634/theoncologist.2017-0072. Epub 2017 Jun 26.
4
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.氟维司群与第三代芳香化酶抑制剂在绝经后晚期乳腺癌女性二线治疗中的比较。
Cancer Treat Rev. 2005 Jun;31(4):274-82. doi: 10.1016/j.ctrv.2005.03.009.
5
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.在绝经后激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌患者中,比较布帕利西布联合氟维司群与安慰剂联合氟维司群的疗效(BELLE-2):一项随机、双盲、安慰剂对照的3期试验。
Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30.
6
Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience.500毫克氟维司群用于绝经后转移性乳腺癌患者:初步临床经验
Breast Cancer. 2016 Jul;23(4):617-23. doi: 10.1007/s12282-015-0612-0. Epub 2015 Apr 21.
7
Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.氟维司群治疗绝经后晚期乳腺癌妇女
Expert Rev Anticancer Ther. 2005 Jun;5(3):445-53. doi: 10.1586/14737140.5.3.445.
8
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.氟维司群(曾用名ICI 182,780)在先前内分泌治疗后病情进展的绝经后晚期乳腺癌女性患者中,其疗效与阿那曲唑相当。
J Clin Oncol. 2002 Aug 15;20(16):3396-403. doi: 10.1200/JCO.2002.10.057.
9
A good drug made better: the fulvestrant dose-response story.一种好药变得更好:氟维司群的剂量反应历程
Clin Breast Cancer. 2014 Dec;14(6):381-9. doi: 10.1016/j.clbc.2014.06.005. Epub 2014 Jun 24.
10
Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.氟维司群是一种用于绝经后晚期乳腺癌女性的有效且耐受性良好的内分泌治疗药物:临床试验结果
Br J Cancer. 2004 Mar;90 Suppl 1(Suppl 1):S11-4. doi: 10.1038/sj.bjc.6601631.